McKesson Closer To Resolving Multi-Year AWP Legal Saga With $190M Federal Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Wholesale drug distributor McKesson settles charges that it reported inflated average wholesale prices (AWPs) for a large number of branded prescription pharmaceuticals, leading to extensive overpayments by the Medicaid program.
You may also be interested in...
AWP Drumbeat Continues With McKesson’s $151 Mil. Medicaid Fraud Settlement With States
The settlement resolves claims McKesson inflated the average wholesale price of more than 1,400 brand drugs.
Senators Seek “Fresh” Ideas To Fight Health Fraud From Stakeholders
An open letter to the “health care community” from a bipartisan group of senators on the Finance Committee asks for white papers offering suggestions on the best ways to combat “the multi-billion dollar problem” of waste, fraud and abuse in Medicare and Medicaid.
OIG And CMS Agree Medicaid Needs National Drug Price Benchmark Based On Acquisition Cost
With First DataBank scheduled to end publishing average wholesale price data in September, there is an opportunity for states to switch to pharmacy reimbursement based on actual acquisition costs.